Jounce Therapeutics, Inc. (JNCE)

Market Cap	96.46M
Revenue (ttm)	82.00M
Net Income (ttm)	-50.92M
Shares Out	52.14M
EPS (ttm)	-0.99
PE Ratio	n/a
Forward PE	19.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,284,590
Open	1.84
Previous Close	1.84
Day's Range	1.84 - 1.86
52-Week Range	0.58 - 7.94
Beta	0.63
Analysts	Buy
Price Target	3.40 (+83.78%)
Earnings Date	May 3, 2023

About JNCE

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2017
• Employees: 137
• Stock Exchange: NASDAQ
• Ticker Symbol: JNCE

Financial Performance

In 2022, JNCE's revenue was $82.00 million, an increase of 204.75% compared to the previous year's $26.91 million. Losses were -$50.92 million, -43.97% less than in 2021.

Analyst Forecast

According to 13 analysts, the average rating for JNCE stock is "Buy." The 12-month stock price forecast is $3.4, which is an increase of 83.78% from the latest price.

Price Target

$3.4

(83.78% upside)

Analyst Consensus: Buy